The Race to Commercialize the World's Most Powerful Psychedelic

"The Race to Commercialize the World's Most Powerful Psychedelic" is a 15-minute Wall Street Journal documentary tracing the effort to turn 5-MeO-DMT, secreted by the Sonoran Desert toad, into an FDA-approved mental health treatment. It moves between a veterans' clinic in Mexico, a Columbia University lab studying the drug's action on the brain, and the biotech executives and federal officials racing to bring a synthetic version to market. The film treats 5-MeO-DMT as both fast-acting and intense, without skipping the risks or who stands to profit.

A last resort in Mexico

The documentary opens at the Mission Within, a Mexico clinic treating veterans with 5-MeO-DMT (also called Bufo, after the toad genus) after "conventional mental health treatments haven't worked." Veterans interviewed describe exhausting SSRIs, SNRIs, talk therapy, and AA before finding 5-MeO-DMT through veteran forums, despite fear of what they'd seen online. The compound is illegal in the US, so clinics like this operate in Mexico, where the film says it remains unregulated; sessions run thousands of dollars, with a roughly six-month wait. Psylopedia's overview of psychedelic legal status by country covers this kind of gap.

A session lasts around 30 minutes, per the film, and can involve physical shaking and loud vocalizing, with prolonged dissociation possible on rare occasions; the Mission Within told WSJ that roughly 5% of patients find it too intense. Several veterans described near-immediate relief, one calling the aftermath like "many years of therapy just in a weekend." Psylopedia's guide to psychedelic safety and harm reduction covers what preparation and support look like for a short, intense experience like this.

What the compound is, and what may be happening in the brain

5-MeO-DMT is a close chemical relative of DMT, though the film shows them as distinct molecules, sketching their structures on a whiteboard. People have reportedly used the compound since the early 1980s, when a man identified in the film as Ken Nelson wrote about extracting and smoking the toad's secretion; it later became shorthand for the pop-culture "toad licking" trope. One veteran described the onset as the "ego" disappearing within seconds, a shift Psylopedia's entry on ego dissolution unpacks further.

Dr. David Langree (as the film identifies him), a psychedelic researcher at Columbia University, has spent five years studying how 5-MeO-DMT acts on the brain. It activates at least two serotonin receptors, including 5-HT1A, the same receptor targeted by antidepressants like buspirone and by psychedelics such as LSD. Why its effects seem to differ from other drugs on that receptor isn't fully understood; he suggests it may come down to potency or the balance of receptors it activates. His lab has reported antidepressant-like effects in mice even with the psychedelic component chemically removed, though he suspects the altered-state experience still plays a role in people. He framed the research as early: "I'm not saying it's a silver bullet," he said, "but it is helpful."

A crowded field racing toward FDA approval

The market opportunity has drawn serious biotech investment. The film profiles Atai Beckley, a public company developing a synthesized 5-MeO-DMT, whose CEO Srinivas Rao says a medical, insurance-reimbursed model could reach 3 to 5 million patients and represent "several billion dollars." Atai Beckley holds the only FDA breakthrough therapy designation for a 5-MeO-DMT compound, meant to speed up review; it raised close to $300 million last year and has since started a phase 3 trial, one of the final steps before approval. The film suggests the drug could reach market in four to five years, barring a major setback.

It isn't alone. GH Research has two 5-MeO-DMT analogues in trials, and AbbVie has acquired a related compound in a deal the film says could top $1 billion. The template several are building toward is Spravato, Johnson & Johnson's ketamine-derived nasal spray, the only psychedelic-adjacent therapy approved so far and now a nearly $2 billion product: patients dosed and monitored for about two hours, then discharged, returning every two to three months instead of taking a daily pill. The film cites a broader psychedelic therapeutics market projected to reach $10 billion by 2034.

Momentum inside Washington

The film also follows the federal side through Matt Zorn, a former legal advocate against Schedule I restrictions who now works inside the Department of Health and Human Services and wrote the executive order President Trump signed in April to expand access to, and research into, psychedelic therapies. Health Secretary Robert Kennedy Jr. is shown saying the department is "working very hard" to make clinical access possible within 12 months. Zorn's framing is pragmatic: with existing treatments failing many patients, he asks, "why wouldn't you want that to be available?" Since the administration took office, stock in companies developing psychedelic therapies has climbed sharply, with Atai Beckley up roughly 250%.

The risks the film keeps in view

Alongside the momentum, the documentary keeps the risks in view. Officials interviewed acknowledge that 5-MeO-DMT can produce "negative adverse events" and so-called bad trips, and stress that the bigger open question is how these therapies "perform out in the wild," beyond a trial's controlled conditions. The Mission Within's own figures, about 5% too intense, and the shaking, loud noises, and occasional prolonged dissociation described on camera are the clearest evidence the film offers of that risk in practice. Until an FDA-approved version reaches the market, unregulated clinics abroad remain, per the film, the only legal route available.

Key takeaways

• ●5-MeO-DMT is a fast-onset, short-duration psychedelic secreted by the Sonoran Desert (Colorado River) toad and also produced synthetically; the documentary describes a typical session lasting around 30 minutes.
• ●It's illegal in the US, so the veterans profiled travel to an unregulated clinic in Mexico, at a cost of thousands of dollars per session and a roughly six-month wait.
• ●Columbia University researcher Dr. David Langree has studied how the compound activates serotonin receptors, including 5-HT1A, though why its effects differ from other drugs on that receptor isn't yet understood.
• ●Multiple biotech companies, including Atai Beckley, GH Research, and AbbVie, are developing 5-MeO-DMT drugs; Atai Beckley is furthest along and holds the only FDA breakthrough therapy designation for the compound.
• ●The proposed commercial model follows Spravato, the ketamine-derived nasal spray already approved for supervised, in-clinic use.
• ●The Trump administration has moved to expand federal support for psychedelic research, and officials in the film say clinical access could broaden within 12 months, though real risks (intense effects, patients who find sessions too intense, unknowns about real-world performance) remain part of the picture.